Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
152 participants
INTERVENTIONAL
2013-10-31
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Blood Levels, Safety, and Tolerability of PF-00734200 in Subjects With Impaired Kidney Function and Normal Kidney Function
NCT00596518
Renal Impairment Study of PF-06700841
NCT04260464
A Renal Impairment Study for PF-04965842
NCT03660241
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
NCT07154901
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
NCT00742716
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fragmin
Fragmin given according to the flexible dosing regimen outlined in the protocol
Fragmin
variable dosing regimen
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fragmin
variable dosing regimen
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal Alexandra Hospital
Edmonton, Alberta, Canada
University of Alberta Hospital
Edmonton, Alberta, Canada
Grey Nuns Community Hospital
Edmonton, Alberta, Canada
Horizon Health Network/Saint John Regional Hospital
Saint John, New Brunswick, Canada
Eastern Regional Health Authority, Health Sciences Centre
St. John's, Newfoundland and Labrador, Canada
Eastern Regional Health Authority, St. Clare's Mercy Hospital
St. John's, Newfoundland and Labrador, Canada
Eastern Regional Health Authority, Waterford Hospital
St. John's, Newfoundland and Labrador, Canada
Queen Elizabeth II Health Sciences Center (QEII) - VG Site
Halifax, Nova Scotia, Canada
William Osler Health System - Bramptom Civic Hospital
Brampton, Ontario, Canada
London Health Sciences Centre, University Hospital
London, Ontario, Canada
London Health Sciences Centre, Kidney Care Centre
London, Ontario, Canada
William Osler Health System
Orangeville, Ontario, Canada
Centre intégré de santé et de services sociaux de la Montérégie-Centre
Greenfield Park, Quebec, Canada
Centre externe de néphrologie CISSS de la Montérégie-Centre
Greenfield Park, Quebec, Canada
Centre Hospitalier de l'Universite de Montreal (CHUM) - Hopital Saint-Luc
Montreal, Quebec, Canada
CIUSSS du Nord-de-l'Ile-de-Montreal
Montreal, Quebec, Canada
CIUSSS du Nord-de-l'Ile-de-Montreal
Montreal, Quebec, Canada
CHU de Quebec (Pavillon Hotel-Dieu de Quebec)
Québec, Quebec, Canada
Centre externe de néphrologie CISSS de la Montérégie-Centre
Saint-Lambert, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Soroka S, Agharazii M, Donnelly S, Roy L, Muirhead N, Cournoyer S, MacKinnon M, Pannu N, Barrett B, Madore F, Tennankore K, Wilson JA, Hilton F, Sherman N, Wolter K, Orazem J, Feugere G. An Adjustable Dalteparin Sodium Dose Regimen for the Prevention of Clotting in the Extracorporeal Circuit in Hemodialysis: A Clinical Trial of Safety and Efficacy (the PARROT Study). Can J Kidney Health Dis. 2018 Nov 4;5:2054358118809104. doi: 10.1177/2054358118809104. eCollection 2018.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A6301091
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.